OncoMatch/Clinical Trials/NCT06980532
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Is NCT06980532 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Glumetinib Combined with Fruquintinib for metastatic colorectal cancer.
Treatment: Glumetinib Combined with Fruquintinib — Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MET amplification (FISH MET GCN≥4 or MET/CEP7≥1.8; Or NGS, ≥20% of tumor cells, ≥200X sequencing depth, GCN≥4)
Have MET amplification (FISH MET GCN≥4 or MET/CEP7≥1.8; Or NGS, ≥20% of tumor cells, ≥200X sequencing depth, GCN≥4)
Required: MET overexpression (IHC 3+ (≥50% of tumor cells strongly positive) or 2+ (≥50% of tumor cells moderately/strongly positive and <50% strongly positive))
overexpression (IHC, 3+(≥50% of tumor cells are strongly positive) or 2+ (≥50% of tumor cells are moderately positive/strongly positive and < 50% of tumor cells are strongly positive); Immunohistochemistry (IHC) detection showed that the MET protein overexpression in the subjects was 3+(strongly positive in ≥50% of tumor cells) or 2+ (positive in ≥50% of tumor cells/weakly positive and strongly positive in < 50% of tumor cells)
Allowed: BRAF mutation
Patients with unresectable metastatic colorectal cancer whose BRAF gene test is mutant and who have not received BRAF inhibitors /MEK inhibitors
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard anti-tumor regimens
Imaging confirmed progression after previous two-line standard anti-tumor regimens
Cannot have received: MET inhibitor
Have received MET inhibitor treatment in the past
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 80 g/L, WBC ≥3.0×10^9/L (no transfusion, blood products, or hematopoietic stimulating factor within 14 days)
Kidney function
Serum creatinine ≤1.5x ULN or creatinine clearance rate ≥50mL/min
Liver function
AST and ALT ≤2.5x ULN (≤5x ULN with liver invasion); serum total bilirubin ≤2x ULN (≤2.5x ULN with liver invasion)
Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L and hemoglobin 80 g/L, white blood cell count (WBC) ≥3.0×10^9/L (corrected by no blood transfusion, no blood products, no use of granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 14 days before laboratory tests); Liver and kidney functions: Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50mL/min; AST and ALT ≤2.5 times the upper limit of normal values (for patients with liver invasion, ≤5 times the upper limit of normal values); Serum total bilirubin ≤2 times the upper limit of normal value (for patients with liver invasion ≤2.5 times the upper limit of normal value); The activated partial thromboplastin time (APTT), International normalized ratio (INR), and prothrombin time (PT) are ≤1.5 times the normal upper limit value.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06980532 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MET inhibitor disqualifies patients from enrollment.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages